Article

Sirion, AVR promote retinal and meibomian gland health

Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR's new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit).

Tampa, FL

-Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR’s new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit). Sirion’s sales force will promote actively the two products as well as provide sampling for the company’s line of topical drops to treat dry eye.

The oral nutritional supplement aims to address the factors that threaten long-term eye and general health. These factors include oxidation, inflammation, and neovascularization, which also are risks in patients with macular degeneration and diabetic retinopathy. The supplement includes a combination of antioxidants, anti-inflammatories, and anti-angiogenics that include fish oil omega-3 fatty acids, vitamin D, green tea extract, and vitamin E.

Meibomitis is a precursor to meibomian gland dysfunction. The condition is characterized by excess bacteria in the eye lid margins, increased vascularization of the lids, and loss of normal meibomian gland anatomy and function, which contribute to decreased quality and quantity of meibomian lips, tear-film lipid layer deficiency, and increased tear-film evaporation. The convenience kit includes doxycycline (75 mg), an omega-3 supplement with optimized flaxseed/fish oil blend (TheraTears Nutrition), and a portable warm compress system for symptom relief (iHeat).

“Sirion and [AVR] share a joint focus on healthy eyes for patients through clinical research and innovation in ocular disease,” said Jeffrey P. Gilbard, MD, founder, chief executive officer, and chief scientific officer of AVR, in a prepared statement. Dr. Gilbard also is a clinical assistant professor of ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center, Boston.

“Sirion’s resources and specialized sales force will be instrumental in helping AVR promote retinal and meibomian gland health and provide relief for dry-eye patients,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.